(Alliance News) - Sareum Holdings PLC on Friday said it will present new preclinical data from its SDC-1802 TYK2/JAK1 inhibitor cancer research programme at the end of October in Boston, US.
The stock was trading 11% higher in London on Friday morning at 0.35 pence a share.
The drug development company said it will participate in a medical conference, where it will describe how SAR-20351, a novel selective TYK2/JAK1 inhibitor discovered by Sareum, reduces tumour growth in various types of cancers.
These positive results were seen when SAR-20351/SDC-1802 was dosed orally, as a monotherapy, or in combination with chemotherapy, Sareum explained.
The studies indicate that inhibition of the TYK2/JAK1 pathway is a novel mechanism that promotes an anti-tumour effect by activating the local immune system to attack cancer cells.
Sareum said these findings provide support for TYK2/JAK1 inhibition as a potential new immunotherapy approach and for the further development of SDC-1802 as a novel cancer therapeutic.
"We are pleased that our research has shown that our TYK2/JAK1 inhibitor, SDC-1802, induces a significant reduction of tumour growth in preclinical models of many cancer types," said Chief Executive Tim Mitchell.
"These encouraging results further support our SDC-1802 TYK2/JAK1 inhibitor cancer programme and we are delighted to be presenting them at this important cancer conference," added Mitchell.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
Sareum (SAR)